Study guide
3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea
MRCPI in General Medicine Part I Written
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Strategy & Foundation
1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy
2 Chapter 2: Cardiology & Vascular Medicine
2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases
3 Chapter 3: Respiratory Medicine
3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea
4 Chapter 4: Gastroenterology & Hepatology
4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition
5 Chapter 5: Nephrology & Acid-Base Disorders
5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders
6 Chapter 6: Endocrinology & Diabetes
6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes
7 Chapter 7: Rheumatology & Clinical Immunology
7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology
8 Chapter 8: Haematology & Medical Oncology
8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies
9 Chapter 9: Neurology & Dermatology
9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease
10 Chapter 10: Acute Medicine, Critical Care & Geriatrics
10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care
11 Chapter 11: Clinical Pharmacology & Therapeutics
11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety
12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics
12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics
3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea
Key Takeaways Explain This Topic AI
In suspected pulmonary embolism, a Wells score >4 indicates PE is likely and warrants immediate CT Pulmonary Angiography (CTPA), whereas a score ≤4 mandates a high-sensitivity D-dimer assay to rule out PE.
Hemodynamically unstable (massive) pulmonary embolism presenting with SBP <90 mmHg or cardiac arrest requires immediate systemic thrombolysis (e.g. alteplase 100 mg IV over 2 hours) or catheter-directed/surgical embolectomy.
Right heart catheterisation is the gold standard diagnostic for pulmonary hypertension, defining PH as a mean pulmonary arterial pressure (mPAP) >20 mmHg at rest; precapillary pulmonary arterial hypertension (PAH) requires mPAP >20 mmHg, pulmonary artery wedge pressure (PAWP) ≤15 mmHg, and pulmonary vascular resistance (PVR) >2 Wood units.
Obstructive sleep apnoea (OSA) severity is graded by the Apnoea-Hypopnoea Index (AHI): normal <5, mild 5–14, moderate 15–29, and severe ≥30 events per hour; Continuous Positive Airway Pressure (CPAP) is the first-line gold standard therapy for moderate-to-severe OSA.
Obesity Hypoventilation Syndrome (OHS) is defined by the triad of BMI ≥30 kg/m², daytime hypercapnia (PaCO2 >6.0 kPa / 45 mmHg), and sleep-disordered breathing in the absence of an alternative hypoventilatory cause.
Last updated: July 2026
Pulmonary Embolism (PE): Risk Stratification, Diagnostic Algorithms & ECG Features
Pulmonary Embolism (PE) is a life-threatening pulmonary vascular emergency resulting from occlusion of the pulmonary arterial bed by thromboemboli, originating primarily from deep vein thrombosis (DVT) of the lower limbs.
Clinical Risk Stratification: The Wells Score
In patients with suspected PE, clinical probability assessment dictates the initial diagnostic path.
- Wells Parameter Score Assigned
- Clinical signs and symptoms of DVT (leg swelling, calf tenderness) +3.0
- PE is the single most likely diagnosis +3.0
- Heart rate >100 beats/minute +1.5
- Immobilisation ≥3 consecutive days OR surgery in previous 4 weeks +1.5
- Previous objectively proven DVT or PE +1.5
- Haemoptysis +1.0
- Active Malignancy (on treatment, palliation, or diagnosed within 6 months) +1.0
- Diagnostic Decision Algorithm
Wells Score >4.0 ("PE Likely") : Proceed directly to CT Pulmonary Angiography (CTPA) . If CTPA is contraindicated (severe renal impairment e.g., eGFR <30 mL/min, contrast anaphylaxis, pregnancy), perform a Ventilation-Perfusion (V/Q) SPECT scan . Therapeutic anticoagulation (e.g., LMWH) should be initiated while awaiting imaging unless contraindicated.
Wells Score ≤4.0 ("PE Unlikely") : Perform a high-sensitivity D-dimer assay .
Negative D-dimer : PE is safely ruled out without imaging.
Positive D-dimer : Proceed to CTPA.
Pulmonary Embolism Rule-out Criteria (PERC)
In patients with a low pre-test probability of PE, the PERC rule can avoid unnecessary D-dimer testing. If ALL 8 criteria are satisfied, PE is ruled out without blood testing:
- Age <50 years,
- Heart rate <100 beats/min,
- SpO2 ≥95% on room air,
- No prior DVT or PE,
- No recent trauma or surgery (<4 weeks),
- No haemoptysis,
- No exogenous estrogen use,
No unilateral leg swelling.
Electrocardiographic (ECG) Manifestations
Sinus Tachycardia : Most common ECG finding (~40% of cases).
Classic S1Q3T3 Pattern : Prominent S wave in lead I, Q wave in lead III, and inverted T wave in lead III (reflects acute cor pulmonale; present in <20% of cases).
Right Ventricular Strain : Right axis deviation, right bundle branch block (RBBB), and T-wave inversions in leads V1–V4 and inferior leads (II, III, aVF).
PE Severity Classification & Emergency Management
PE is classified by hemodynamic stability and mortality risk to guide escalation of therapeutic intervention.
PE Risk Category Hemodynamic Status Biomarkers & RV Imaging First-Line Emergency Management
Massive PE (High-Risk) Unstable : Systolic BP <90 mmHg or SBP drop ≥40 mmHg for >15 mins RV dilation/dysfunction present; Troponin / NT-proBNP elevated Immediate Systemic Thrombolysis (Alteplase 100 mg IV over 2 hours) or Surgical/Catheter Embolectomy
Submassive PE (Intermediate-Risk) Stable : Systolic BP ≥90 mmHg Positive : RV strain on echo/CT AND/OR elevated Troponin / NT-proBNP Therapeutic LMWH or DOAC with telemetry monitoring; rescue thrombolysis if unstable
Low-Risk PE Stable : Systolic BP ≥90 mmHg Negative : Normal RV size and normal troponin levels Direct Oral Anticoagulant (DOAC: Apixaban, Rivaroxaban) or LMWH bridged to Warfarin
Thrombolysis Protocol : In massive PE with cardiogenic shock, Alteplase 100 mg IV over 2 hours (or 0.6 mg/kg bolus over 15 minutes during cardiac arrest) is administered alongside Unfractionated Heparin (UFH). UFH is preferred over LMWH due to its short half-life and complete reversibility with protamine sulphate.
Anticoagulation Duration
Provoked PE (transient major risk factor e.g., surgery, trauma, immobilisation): 3 months of anticoagulation.
Unprovoked PE or ongoing persistent risk factor (active cancer, antiphospholipid syndrome): Indefinite (long-term) anticoagulation.
Pulmonary Hypertension (PH): Definition, Classification & Targeted Therapies
Pulmonary Hypertension is defined hemodynamically via Right Heart Catheterisation (RHC) as a Mean Pulmonary Arterial Pressure (mPAP) >20 mmHg at rest .
Clinical Classification (5 ESC/ERS Groups)
Group 1: Pulmonary Arterial Hypertension (PAH) : Precapillary PH defined by mPAP >20 mmHg , Pulmonary Artery Wedge Pressure ( PAWP ≤15 mmHg ), and Pulmonary Vascular Resistance ( PVR >2 Wood units ).
Etiologies : Idiopathic PAH, heritable ( BMPR2 mutation), drug/toxin-induced (methamphetamine, appetite suppressants), connective tissue disease (Systemic Sclerosis), HIV infection, portal hypertension.
Group 2: PH Secondary to Left Heart Disease : Postcapillary PH ( PAWP >15 mmHg ). Most common overall cause (HFpEF, HFrEF, mitral/aortic valve disease).
Group 3: PH Secondary to Lung Disease / Hypoxia : Precapillary PH due to COPD, ILD, or OSA.
Group 4: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) : Precapillary PH caused by non-resolving organized thromboemboli. Diagnosed via V/Q scan showing unmatched perfusion defects. Potentially cured by Pulmonary Endarterectomy (PEA) .
Group 5: PH with Unclear / Multifactorial Mechanisms : Hematologic, systemic, or metabolic disorders.
Targeted PAH Pharmacotherapy (Group 1 Only)
Endothelin Receptor Antagonists (ERAs) : Bosentan (dual ET-A/ET-B antagonist; requires monthly LFT monitoring due to hepatotoxicity), Ambrisentan (selective ET-A), Macitentan .
Phosphodiesterase-5 (PDE-5) Inhibitors : Sildenafil , Tadalafil (increase cGMP to promote pulmonary vasodilation).
Soluble Guanylate Cyclase (sGC) Stimulators : Riociguat (directly stimulates sGC to produce cGMP; approved for Group 1 PAH and inoperable Group 4 CTEPH; contraindicated with PDE-5 inhibitors).
Prostacyclin Analogues & Receptor Agonists : Epoprostenol (continuous IV infusion), Iloprost (inhaled), Treprostinil , Selexipag (oral IP receptor agonist).
Obstructive Sleep Apnoea (OSA) & Obesity Hypoventilation Syndrome (OHS)
Obstructive Sleep Apnoea (OSA) involves recurrent upper airway collapse during sleep, causing apnoeas (airflow cessation ≥10 sec) and hypopnoeas (≥30% airflow reduction with ≥3% oxygen desaturation or arousal).
Clinical Features & Diagnostic Grading
Symptoms : Excessive daytime sleepiness (evaluated using the Epworth Sleepiness Scale [ESS] , score >10 indicates excessive sleepiness), loud snoring, witnessed apnoeic pauses, morning headaches, nocturia, and impaired concentration.
Polysomnography (PSG) : Evaluates the Apnoea-Hypopnoea Index (AHI) (number of apnoeas and hypopnoeas per hour of sleep):
- Normal : AHI <5 events/hour
- Mild OSA : AHI 5–14 events/hour
- Moderate OSA : AHI 15–29 events/hour
- Severe OSA : AHI ≥30 events/hour
- Management & Regulatory Driving Standards
Continuous Positive Airway Pressure (CPAP) : First-line gold standard therapy for moderate-to-severe OSA or symptomatic mild OSA. Pneumatically splints the pharyngeal airway open.
Mandibular Advancement Devices (MAD) : Custom oral appliances that advance the mandible, indicated for mild-to-moderate OSA or CPAP-intolerant patients.
Obesity Hypoventilation Syndrome (OHS / Pickwickian Syndrome) : Defined by the triad of:
- BMI ≥30 kg/m² ,
- Daytime hypercapnia (PaCO2 >6.0 kPa / 45 mmHg) , and
Sleep-disordered breathing in the absence of alternative hypoventilatory causes. Treatment : Non-Invasive Ventilation (NIV / BiPAP) and targeted weight reduction.
Driver Licensing Regulations (DVLA / Irish RSA Rules) : Patients diagnosed with OSA associated with excessive daytime sleepiness MUST cease driving immediately and notify the national driver licensing authority. Driving may resume only when sleepiness is fully controlled with documented CPAP adherence and medical confirmation.